Document is current
Any future updates will be listed below
-
Authors
Garber, John J.
Roelstraete, Bjorn
Lochhead, Paul J.
Uchida, Amiko M.
Michaëlsson, Karl
Olén, Ola
Ludvigsson, Jonas F. https://orcid.org/0000-0003-1024-5602
-
Funding
Funding for this research was provided by:
Karolinska Institute
- License Information
-
More Information
Article History
Received: 5 January 2022
Accepted: 30 May 2022
First Online: 28 June 2022
Declarations
:
: The study was approved by the Regional Ethics Committee, Stockholm, Sweden (Protocol no 2014/1287-31/4).
: Dr. Garber has received research support from the American Partnership for Eosinophilic Disorders (APfED) and Takeda Pharmaceuticals. Dr. Olén has been PI on projects partly financed by investigator-initiated grants from Janssen and Ferring, and also on a grant from Pfizer in the context of a national safety monitoring program. None of those studies have any relation to the present study. Karolinska Institutet has received fees for lectures and participation on advisory boards from Janssen, Ferring, Takeda, and Pfizer regarding topics not related to the present study. Dr Uchida is on a Medical Advisory Board for Sanofi-Regeneron (unrelated to this study). Dr. Ludvigsson coordinates a study on behalf of the Swedish IBD quality register (SWIBREG). That study has received funding from Janssen corporation.
